About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
April 2024 M T W T F S S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Twitter List
Legislative Tracking Tools
Category Archives: DTC Advertising
Perspectives on DTC Perspectives
Yesterday I had the good fortune to participate on a panel staged at the National DTC Perspectives Conference held here in Washington. The conference was impressive not only because of the size and scope of the turnout – hundreds … Continue reading
Posted in DTC Advertising, FDA Policy
2 Comments
FDA Staffing Provides Insight into Future Changes Affecting DTC
This week it was announced that a senior fellow from the office of Senator Edward Kennedy would be heading back to FDA as a senior counselor to Dr. Joshua Sharfstein where it is reported that the FDA Office of Legislative … Continue reading
Posted in DTC Advertising, FDA Policy
Comments Off on FDA Staffing Provides Insight into Future Changes Affecting DTC
DTC in the Crosshairs of Congressman Waxman
Reuters carried a report yesterday confirming not only that a moratorium on Direct-to-Consumer (DTC) advertising is likely to be introduced in the next Congress, but is going to be broached by Congressman Henry Waxman, the new Chair of the House … Continue reading
Posted in DTC Advertising
1 Comment
Change is in the Air
Yesterday I gave a brief talk at the DTC Perspectives conference held in New Jersey called DTC in the Era of Consumer Choice. I thought I’d outline a few of my thoughts on the future of DTC here as well. … Continue reading
Posted in DTC Advertising
2 Comments
Rule by Committee – Curbing DTC Advertisting by Pharmas – Enough to Stave Off Reforms?
Advertising Age carried a June 16 story regarding an agreement by several pharmaceutical manufacturers to curb DTC advertising. Here is a bit of the history of this agreement according to the Energy and Commerce Web site. Early this year, Representatives … Continue reading
Posted in DTC Advertising
Comments Off on Rule by Committee – Curbing DTC Advertisting by Pharmas – Enough to Stave Off Reforms?